Peter Thiel joins board of antibody therapy developer AbCellera

(Reuters) - Billionaire venture capitalist Peter Thiel has joined AbCellera Biologics Inc's board of directors, the Canadian antibody therapy developer said on Thursday.

Thiel, who has backed several startups as they went public, is an existing investor in AbCellera. He joins the startup's board a couple of months after Reuters reported that it had hired investment banks for a U.S. initial public offering, which could come this year.

AbCellera has been working with Eli Lilly and Co (NYSE: LLY) to develop a treatment for the novel coronavirus.

Thiel is known for his early investments in Facebook (NASDAQ: FB) and co-founding electronic payment service provider Paypal Inc (NASDAQ: PYPL). In September, he took data analytics firm Palantir Technologies Inc (NYSE: PLTR) public through a direct-listing.

(Reporting by Tiyashi Datta in Bengaluru; Editing by Amy Caren Daniel)

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Nuclear fuel firm Standard Nuclear eyes up to $3.55 billion valuation in US IPO
• French court shortens Le Pen's ban from office but orders electronic tag
• France's debt burden at risk of snowballing ahead of 2027 election